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ditorialhould  the  prescription  of oral anticancer  drugs  be
estricted?.  Introduction
n the year 2010, the Spanish Society of Medical Oncol-
gy (SEOM) published an editorial1 in the Annals of Oncology
ntitled “Treatment of cancer with oral drugs: a position state-
ent by the Spanish Society of Medical Oncology”. The main
remise of the editorial was a call to grant medical oncologists
he exclusive right to prescribe all anticancer drugs, whether
dministration is intravenous or oral. As might be expected,
hat editorial has ignited a ﬁerce and ongoing debate in
pain.
The ﬁrst medical society to respond was the Spanish Soci-
ty of Radiation Oncologists (SEOR) via a letter to the editor2
o rebut the radical stance taken by the SEOM. The SEOR also
ollowed up that letter with an editorial in the Spanish jour-
al Clinical and Translational Oncology (CTO).3 Several months
ater, endocrinologists representing the Spanish Society of
ndocrinology and Nutrition (SEEN) also responded to the orig-
nal SEOM editorial with a letter to the editor of Annals of
ncology.4
We  believe that the outcome of this intense debate, which
s taking place in a well-known international journal, has
mplications for all specialists who currently prescribe oral
nticancer medications.
. Interdisciplinary  approach
ancer is a complex disease requiring the intervention of spe-
ialists from many  different ﬁelds. Awareness of the need for a
ollaborative approach to cancer care has increased dramati-
ally in recent decades.5–7 All of the Spanish medical societies
nvolved in cancer care (including the SEOR and SEOM) made
n explicit commitment to this approach at a conference
rganized by the Spanish Ministry of Health. The conclusion
f that meeting was the approval (and subsequent publica-
ion) of a position statement titled “Institutional declaration
n favour of the development of interdisciplinary cancer care in
pain”.8This declaration makes it clear that the treatment and
care of patients with cancer requires an interdisciplinary
approach involving a wide range of specialists: haematolo-
gists, radiation oncologists, endocrinologists, pulmonologists,
neurologists, gynaecologists, rheumatologists, dermatolo-
gists, gastroenterologists, and others. Each specialty has
unique knowledge and skills and all have important contri-
butions to make. Most specialists are well-acquainted with
this interdisciplinary model because they participate in it on a
daily basis through multidisciplinary tumour boards and clin-
ical treatment units.9,10
Despite the growing appreciation and support for the
interdisciplinary approach, the SEOM editorial appears to pro-
pose an outdated model in which care would be centred
around a single specialist, the medical oncologist. As radi-
ation oncologists, we know that cancer treatment must be
interdisciplinary, and we certainly see little value in narrowly
restricting the prescription of oral drugs to a small minority of
physicians.11 Indeed, if such restrictions were to be imposed,
the result would surely be counterproductive, as specialists
would be forced to refer any patient needing medical treat-
ment to a medical oncologist, thus leading to an increase the
number of patient consultations, costs, and waiting times. All
of this would delay treatment and, in all likelihood, worsen
outcomes.
3.  Are  patients  really  at  risk?
The main argument given to support imposing restrictions on
the right to prescribe anticancer drugs is patient safety. How-
ever, radiation oncologists (and other specialists) have been
routinely prescribing anticancer drugs for decades now, with-
out any harm to patients. Unsubstantiated claims of “patient
risk” are poor arguments; moreover, as highly trained spe-
cialists, we ﬁnd these claims to be disrespectful. Radiation
oncologists receive extensive training in oncology (and in
internal medicine) and radiotherapy, and we are eminently
prepared to prescribe and monitor the use of anticancer med-
ications.
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4.  Why  now?
It seems reasonable to ask why medical oncologists suddenly
seem so concerned with restricting the right to prescribe oral
drugs. Patient safety cannot be the real issue, as we explained
in the preceding paragraph. Could the real issue be that medi-
cal oncologists perceive that oral drugs and targeted therapies
present a threat to their specialty? Intravenous administra-
tion of drugs is a technique that requires specialized skills and
knowledge. However, times have changed and improvements
in the bioavailability of new drugs make it possible to deliver
most chemotherapy agents orally. Moreover, the increasing
use of targeted molecular agents (delivered orally) reduces the
need for intravenous delivery. It would appear then that the
ﬁercely protective and restrictive stance of medical oncolo-
gists is a misguided form of self-protection.
5.  Other  arguments
One proposal put forth in the SEOM editorial is that medi-
cal oncologists should have a role that is analogous to that of
a family doctor, with the overall treatment of cancer coordi-
nated by the medical oncologist. Although this idea has some
merit, we  believe that it would lead, inevitably, to redundancy;
patients would be shuttled back and forth between the “can-
cer doctor” and the various specialists. In our opinion, it would
make more  sense to assign a primary physician based on the
main treatment modality (surgical, medical, or radiotherapeu-
tic). The primary physician could thus be a surgeon, a radiation
oncologist, a haematologist or other specialist depending on
the illness and likely treatment. In any case, since 60% of all
cancers are also treated by radiotherapy,3 it would make more
sense to assign the radiation oncologist as the primary physi-
cian in most cases, particularly because radiation oncologists
are, as the name implies, also oncologists.
A ﬁnal “argument” made in the SEOM editorial is that
research and clinical care must be linked. In this vision of
care, medical oncologists would be optimally positioned to
evaluate clinical response, protocol adherence, and the inclu-
sion of patients in clinical trials. However, as the authors must
surely be aware, clinical trials are necessarily interdisciplinary
events, and treating cancer patients requires an interdisci-
plinary approach. No single specialist can or should control
the treatment.
6.  Conclusion
It is important to point out that limiting prescription rights to
medical oncologists would contradict the Core Curriculum of
European Radiation Oncologists, which was recently revised
and approved by most European countries.12 This curriculum
clearly states that the radiation oncologist is responsible for
the delivery of drugs when combined with radiotherapy, in
collaboration with other specialists, if appropriate. Current
clinical practice in radiotherapy requires the prescription of
oral medications, and restrictions would severely hamper our
ability to effectively treat patients. Moreover, the specialty
of Radiation Oncology in Spain and in the European Union
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includes training in chemotherapy, new biological drugs, and,
especially, in combined radio-chemotherapy treatments.13
The proposed restrictions directly challenge Article 23 of
the Spanish Code of Medical Deontology14 (July 2011), which
speciﬁcally and unequivocally states that “the physician must
have the right to prescribe medications, respecting the scien-
tiﬁc evidence and authorized indications, that allows him/her
to act independently and to guarantee quality”.
To conclude, we do not expect these misguided efforts to
restrict our ability to prescribe oral drugs to succeed. Yet we
believe that vigilance is necessary. What is happening in Spain
is, at the moment, only a local problem. However, unless we
take a stand now, this campaign to restrict our rights could
gain momentum and eventually become an important prob-
lem in other European countries.
We realize that the views expressed in this editorial may
not be shared by all. Healthy debate is important to scientiﬁc
progress, and we encourage readers who wish to voice their
opinions to submit a letter to the Editor.
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